When a pharmaceutical company’s marketing materials start sounding more like a miracle cure infomercial than a science-based disclosure, red flags should fly. This is precisely the scenario unfolding around ImmunityBio, a San Diego–based biotech firm whose lead drug, Anktiva, recently found itself at the center of an FDA warning letter — and a swelling class action lawsuit.
Investors who bought ImmunityBio stock between January 19 and March 24, 2026, now have until this Tuesday, May 26, to step forward as lead plaintiffs in a securities fraud case that alleges the company misled the public about what Anktiva can actually do. The lawsuit, filed in the Central District of California, claims that ImmunityBio and its executive chairman, Dr. Patrick Soon-Shiong, made statements that dramatically overstated the drug’s capabilities. Among the most troubling allegations: that Anktiva was promoted as a cancer vaccine capable of making patients “cancer-free for the long term,” a claim that has not been clinically demonstrated, according to the complaint.
The FDA Letter That Shook the Stock
The trouble became public on March 24, when a warning letter from the FDA — dated March 13 — was released. In it, the agency accused the company of misbranding Anktiva through a television ad and podcast, creating “a misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer.” The stock price promptly dropped 21% on the news, erasing significant shareholder value.
This isn’t just a regulatory slap on the wrist. It’s a stark reminder that when hype outpaces evidence, investors can get burned. The issue at hand is not whether Anktiva has legitimate therapeutic use — it is approved for a specific form of non-muscle invasive bladder cancer (NMIBC). The question is whether the company’s public statements crossed the line from hopeful possibility into outright misrepresentation, potentially violating the Securities Exchange Act of 1934.
What Investors Need to Know Now
Under the Private Securities Litigation Reform Act of 1995, anyone who purchased ImmunityBio shares during the defined class period can seek to become the lead plaintiff. This role goes to the investor or group with the largest financial stake who is also deemed typical and adequate to represent the class. Importantly, you do not need to be lead plaintiff to share in any eventual recovery — but the lead plaintiff does get to choose the law firm that will steer the case.
Robbins Geller Rudman & Dowd, the firm announcing the deadline, is no small player. They ranked first in the ISS Securities Class Action Services Top 50 Report last year, recovering over $916 million for investors in 2025 alone. They have a track record of taking on major securities fraud cases, including the historic $7.2 billion Enron settlement. While past results don’t guarantee future outcomes, their involvement signals a serious pursuit.
The Bigger Picture: When Biotech Hype Outruns Science
This case fits a troubling pattern in the biotech sector. Desperate patients and optimistic investors are often drawn to breakthrough narratives, especially around cancer treatments. Companies know this. The temptation to stretch language — calling a treatment a “vaccine” when it is not, or implying a cure where only disease management has been shown — can be enormous. But the consequences are equally large. The FDA warning letter explicitly called the promotional materials a public health concern, not just a legal one.
For the average investor, this lawsuit underscores a crucial lesson: regulatory scrutiny is one of the fastest ways to separate fact from fiction in drug development. Stock prices often rise on promise and plummet on proof. Those who bought ImmunityBio shares during the class period are now left holding the bag, wondering whether the company’s rosy projections were simply too good to be true.
Time is running out to act. The lead plaintiff deadline is May 26. If you’re among those who suffered substantial losses, contacting an attorney — such as Ken Dolitsky or Michael Albert at Robbins Geller (800/851-7783) — is a logical next step. But beyond the legal maneuvering, this case serves as a broader warning: in the high-stakes world of biotech investing, due diligence isn’t optional. Because when a company’s claims outpace its data, the cure for your portfolio might be a lawsuit — not a miracle drug.
